Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 5
2022 3
2023 3
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Activation of Tumor-Cell STING Primes NK-Cell Therapy.
Knelson EH, Ivanova EV, Tarannum M, Campisi M, Lizotte PH, Booker MA, Ozgenc I, Noureddine M, Meisenheimer B, Chen M, Piel B, Spicer N, Obua B, Messier CM, Shannon E, Mahadevan NR, Tani T, Schol PJ, Lee-Hassett AM, Zlota A, Vo HV, Ha M, Bertram AA, Han S, Thai TC, Gustafson CE, Venugopal K, Haggerty TJ, Albertson TP, Hartley AV, Eser PO, Li ZH, Cañadas I, Vivero M, De Rienzo A, Richards WG, Abu-Yousif AO, Appleman VA, Gregory RC, Parent A, Lineberry N, Smith EL, Jänne PA, Miret JJ, Tolstorukov MY, Romee R, Paweletz CP, Bueno R, Barbie DA. Knelson EH, et al. Cancer Immunol Res. 2022 Aug 3;10(8):947-961. doi: 10.1158/2326-6066.CIR-22-0017. Cancer Immunol Res. 2022. PMID: 35678717 Free PMC article.
GPRC5D-Targeted CAR T Cells for Myeloma.
Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, Wilcox JA, Santomasso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Giralt SA, Park JH, Usmani SZ, Rivière I, Brentjens RJ, Smith EL. Mailankody S, et al. N Engl J Med. 2022 Sep 29;387(13):1196-1206. doi: 10.1056/NEJMoa2209900. N Engl J Med. 2022. PMID: 36170501 Free PMC article. Clinical Trial.
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.
Fernández de Larrea C, Staehr M, Lopez AV, Ng KY, Chen Y, Godfrey WD, Purdon TJ, Ponomarev V, Wendel HG, Brentjens RJ, Smith EL. Fernández de Larrea C, et al. Blood Cancer Discov. 2020 Sep;1(2):146-154. doi: 10.1158/2643-3230.BCD-20-0020. Blood Cancer Discov. 2020. PMID: 33089218 Free PMC article.
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.
Coffey DG, Maura F, Gonzalez-Kozlova E, Diaz-Mejia JJ, Luo P, Zhang Y, Xu Y, Warren EH, Dawson T, Lee B, Xie H, Smith E, Ciardiello A, Cho HJ, Rahman A, Kim-Schulze S, Diamond B, Lesokhin A, Kazandjian D, Pugh TJ, Green DJ, Gnjatic S, Landgren O. Coffey DG, et al. Nat Commun. 2023 Sep 2;14(1):5335. doi: 10.1038/s41467-023-40966-8. Nat Commun. 2023. PMID: 37660077 Free PMC article.
Future of CAR T cells in multiple myeloma.
Wudhikarn K, Mailankody S, Smith EL. Wudhikarn K, et al. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):272-279. doi: 10.1182/hematology.2020000111. Hematology Am Soc Hematol Educ Program. 2020. PMID: 33275747 Free PMC article. Review.
Beyond BCMA: newer immune targets in myeloma.
Tan MSY, Chen Y, Smith EL. Tan MSY, et al. Blood Adv. 2024 Aug 27;8(16):4433-4446. doi: 10.1182/bloodadvances.2023010856. Blood Adv. 2024. PMID: 38865708 Free PMC article. Review.
15 results